These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38693736)

  • 1. Applications of Inorganic Nanomaterials against Tuberculosis: A Comprehensive Review.
    Dastidar DG; Roy A; Ghosh G; Mandal S
    Curr Drug Deliv; 2024 Apr; ():. PubMed ID: 38693736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanocarriers in Tuberculosis Treatment: Challenges and Delivery Strategies.
    Kumar M; Virmani T; Kumar G; Deshmukh R; Sharma A; Duarte S; Brandão P; Fonte P
    Pharmaceuticals (Basel); 2023 Sep; 16(10):. PubMed ID: 37895831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Anti-Mycobacterial Activity Of Ag, ZnO, And Ag- ZnO Nanoparticles Against MDR- And XDR-
    Heidary M; Zaker Bostanabad S; Amini SM; Jafari A; Ghalami Nobar M; Ghodousi A; Kamalzadeh M; Darban-Sarokhalil D
    Infect Drug Resist; 2019; 12():3425-3435. PubMed ID: 31807033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extensively drug-resistant tuberculosis: epidemiology and management.
    Matteelli A; Roggi A; Carvalho AC
    Clin Epidemiol; 2014; 6():111-8. PubMed ID: 24729727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidrug and extensively drug-resistant TB (M/XDR-TB): problems and solutions.
    Prasad R
    Indian J Tuberc; 2010 Oct; 57(4):180-91. PubMed ID: 21141336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region.
    Dreyer V; Mandal A; Dev P; Merker M; Barilar I; Utpatel C; Nilgiriwala K; Rodrigues C; Crook DW; ; Rasigade JP; Wirth T; Mistry N; Niemann S
    Genome Med; 2022 Aug; 14(1):95. PubMed ID: 35989319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective drug deposition in lungs through pulmonary drug delivery system for effective management of drug-resistant TB.
    Sankhe K; Khan T; Bhavsar C; Momin M; Omri A
    Expert Opin Drug Deliv; 2019 May; 16(5):525-538. PubMed ID: 31007100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characterization of mutations associated with resistance to second-line tuberculosis drug among multidrug-resistant tuberculosis patients from high prevalence tuberculosis city in Morocco.
    Oudghiri A; Karimi H; Chetioui F; Zakham F; Bourkadi JE; Elmessaoudi MD; Laglaoui A; Chaoui I; El Mzibri M
    BMC Infect Dis; 2018 Feb; 18(1):98. PubMed ID: 29486710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal.
    Cohen KA; Abeel T; Manson McGuire A; Desjardins CA; Munsamy V; Shea TP; Walker BJ; Bantubani N; Almeida DV; Alvarado L; Chapman SB; Mvelase NR; Duffy EY; Fitzgerald MG; Govender P; Gujja S; Hamilton S; Howarth C; Larimer JD; Maharaj K; Pearson MD; Priest ME; Zeng Q; Padayatchi N; Grosset J; Young SK; Wortman J; Mlisana KP; O'Donnell MR; Birren BW; Bishai WR; Pym AS; Earl AM
    PLoS Med; 2015 Sep; 12(9):e1001880. PubMed ID: 26418737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment efficacy of drug-resistant tuberculosis in Bashkortostan, Russia: A retrospective cohort study.
    Yunusbaeva M; Borodina L; Alekseev P; Davydov R; Yunusbaev U; Sharipov R; Bilalov F; Yunusbayev B
    Int J Infect Dis; 2019 Apr; 81():203-209. PubMed ID: 30794942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced drug delivery and therapeutic strategies for tuberculosis treatment.
    Nair A; Greeny A; Nandan A; Sah RK; Jose A; Dyawanapelly S; Junnuthula V; K V A; Sadanandan P
    J Nanobiotechnology; 2023 Nov; 21(1):414. PubMed ID: 37946240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracellular Activity of Poly (DL-Lactide-co-Glycolide) Nanoparticles Encapsulated with Prothionamide, Pyrazinamide, Levofloxacin, Linezolid, or Ethambutol on Multidrug-Resistant
    Jiang H; Li X; Xing Z; Niu Q; Xu J
    Curr Drug Deliv; 2023; 20(3):306-316. PubMed ID: 35546770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force.
    Centers for Disease Control and Prevention (CDC)
    MMWR Recomm Rep; 2009 Feb; 58(RR-3):1-43. PubMed ID: 19214162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in nanotechnology-based carrier systems for targeted delivery of bioactive drug molecules with special emphasis on immunotherapy in drug resistant tuberculosis - a critical review.
    Singh J; Garg T; Rath G; Goyal AK
    Drug Deliv; 2016 Jun; 23(5):1676-98. PubMed ID: 26289212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emergence of extensively drug-resistant tuberculosis (TB): TB/HIV coinfection, multidrug-resistant TB and the resulting public health threat from extensively drug-resistant TB, globally and in Canada.
    Alexander PE; De P
    Can J Infect Dis Med Microbiol; 2007 Sep; 18(5):289-91. PubMed ID: 18923728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis.
    Ahmad S; Mokaddas E
    J Infect Public Health; 2014; 7(2):75-91. PubMed ID: 24216518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of tetracycline analogs against multidrug-resistant and extensive drug resistance clinical isolates of Mycobacterium tuberculosis.
    Zhang C; Ouyang Q; Zhou X; Huang Y; Zeng Y; Deng L; Lin D; Zheng W
    Tuberculosis (Edinb); 2023 May; 140():102336. PubMed ID: 36963294
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.